Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX) following Q4 results

Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $9.00 price target on Compass Therapeutics (NASDAQ: CMPX)

The analyst commented, "Thursday, before the market open, Compass Therapeutics reported 4Q25 financial results. Management did not host a call. The company reported a 4Q25 net loss of $15.7M vs. our estimate of $16.1M and FY2025 EPS of $(0.42) vs. our projected $(0.44). To end 2025, Compass had ~$209M in cash and equivalents on hand, which is guided to provide runway into 2028. The most notable development is that the trigger for the OS/PFS analysis of COMPANION-002 has been hit and data will come during April. Predicated on positioning of tovecimig relative to standard therapy in 2L BTC and pipeline optionality, balanced by binary risk for the COMPANION-002 readout, we maintain our Outperform rating and $9 price target."

For an analyst ratings summary and ratings history on Compass Therapeutics click here. For more ratings news on Compass Therapeutics click here.

Shares of Compass Therapeutics closed at $5.69 yesterday.

You May Also Be Interested In

• Barrick Is Said to Weigh Delaying North America Gold IPO to 2027 - Bloomberg
• Quanome Technologies (QNME) files $250M mixed shelf
• National Health Investors (NHI) PT Lowered to $80 at Truist Securities